SOPHiA GENETICS Reports Third Quarter 2026 Results
PR Newswire•03/11/2026•06:45 ET
0
Key Highlights
- ➤Q3 revenue $24.3 million, up 25% year-over-year
- ➤Adjusted EBITDA loss $6.1 million, improving 31% year-over-year
- ➤FY 2026 revenue expected at upper end of $94 million-$96 million guidance
- ➤Full-year adjusted EBITDA loss forecast at $29 million-$32 million
- ➤AstraZeneca multi-year agreement launches two companion diagnostic programs
Expert Statements
Ross Muken, Chief Executive Officer of SOPHiA GENETICS
“Record analysis volume, strong performance in the U.S. market, and accelerating BioPharma momentum resulted in another excellent quarter as revenue grew 25% year-over-year,”
Ross Muken, Chief Executive Officer of SOPHiA GENETICS
“We also meaningfully improved adjusted EBITDA by 31%, bringing us closer to profitability and further demonstrating the highly scalable nature of our AI-native platform and business model.”
Ross Muken, Chief Executive Officer of SOPHiA GENETICS
“Looking ahead, new geographies, exciting new products, and expanded relationships with BioPharma offer meaningful catalysts for future growth. We signed 30 new genomics customers in Q3 and closed three material BioPharma deals, including two companion diagnostic programs and a new, multimodal AI project announced today. These partnerships position us well for 2027 and further extend the reach of our clinical intelligence to more patients worldwide.”
SOPHiA GENETICS Reports Third Quarter 2026 Results PR Newswire
BOSTON and ROLLE, Switzerland, Nov. 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.